This limited or inaccurate mapping is especially true for any signal capture that occurs in the lower ranges below 100µV (microvolts), which leads to the second problem. Most simple arrhythmia issues are found to be in the area above the 100µV range and as high as 1000µV. These large signals are easily able to be seen above the noise threshold so the EP physician can determine where ablation can be effective. But for the 35% of patients who suffer from complex arrhythmias, traditional ablation therapy is no ...

One substantial savings recognized is for the successful termination of the office lease expense for the former headquarters in Westport, Connecticut as of July 15, 2024 which was set to end on December 31, 2024. BioSig's CEO, Anthony Amato stated, "Maintaining a strong and flexible balance sheet is a priority for our new management team. In a difficult market for companies like ours, we look for other ways to help our company and its shareholders. This reduction will provide more flexibility in evaluating ...

As filed with the Securities and Exchange Commission on July 23, 2024 Registration No. 333-280525 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BioSig Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 3845 26-4333375 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification ...

As filed with the Securities and Exchange Commission on June 27, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 UNDER THE SECURITIES ACT OF 1933 BioSig Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Delaware 3845 26-4333375 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 55 Greens Farms Road, 1st Floor Westport, C ...

Personal Bio, Ferdinand Groenewald, age 39 Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at ...

Personal Bio, Ferdinand Groenewald, age 39 Ferdinand Groenewald is a certified public accountant with significant experience in finance and accounting. He currently serves as Vice President, Finance at Alaunos Therapeutics, Inc. Previously, Mr. Groenewald served as an Independent Outside Director at SYLA Technologies Co., Ltd.; an Independent Director at HeartCore Enterprises, Inc.; an Independent Director at Sushi Ginza Onodera, Inc.; an Accountant at Wrinkle, Gardner & Co. PC; a Senior Staff Accountant at ...

Westport, CT, May 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company") a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 1,570,683 shares of its common stock at a purchase price of $1.91 per share and concurrent private placement unregistered warr ...

Westport, CT, May 21, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or "Company"), a medical technology company delivering unprecedented accuracy and precision to intra- cardiac signal visualization, has today issued the following Letter to Shareholders: Dear Shareholders, As the new CEO of BioSig, I am committed to keeping our shareholders updated to the best of my ability on the progress of our Company. Our new management team is firmly committed to both restoring and creatin ...

Core Viewpoint - BioSig Technologies, Inc. is focused on enhancing shareholder value through new management initiatives and operational improvements, particularly in its PURE EP™ Biomedical Signal Processing Technology [1][4]. Group 1: Management and Governance - The newly assembled Board of Directors includes five experienced individuals, with three serving as independent directors, and all committees have been fully constituted [3]. - A revamped Business Advisory Board is being formed to explore business opportunities and potential mergers and acquisitions [3]. Group 2: Operational Focus - Despite recent leadership changes, the company remains committed to its core business and continues to maintain partnerships with major institutions in the electrophysiology sector [4]. - The company is actively working to demonstrate the value of its PURE EP platform to stakeholders and shareholders [4]. Group 3: Technology and Innovation - BioSig sees significant opportunities in the AI sector, particularly in generative data compilation and commercialization through proprietary algorithms for interventional cardiology [5]. - The PURE EP™ Platform is an FDA 510(k) cleared non-invasive class II device that enhances real-time signal visualization for cardiac ablation procedures [8]. Group 4: Compliance and Financial Health - The company presented to the Nasdaq Hearings Panel and has regained compliance with the minimum bid price requirement [6]. - Ongoing updates will be provided to shareholders regarding compliance issues following the hearing [6].

25 BioSig AI is obligated to pay Reified a monthly consulting fee of $30,000. At March 31, 2024 December 31, 2023, accounts payable due under the contract was $90,000. As of March 31, 2024, the Company had aggregate purchase commitments of approximately $1,759,385 for future services or products, some of which are subject to modification or cancellations. On February 22, 2024, the Company received a threat of litigation seeking restitution for losses resulting from unlawful actions taken by the Company's bo ...